+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Atrial Fibrillation Market to 2027 - Global Analysis and Forecasts By Treatment Type; End User and Geography

  • ID: 5006428
  • Report
  • February 2020
  • Region: Global
  • 147 pages
  • The Insight Partners
UP TO OFF
until Sep 30th 2020
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott
  • AtriCure, Inc
  • Biosense Webster, Inc.
  • Biotronik Inc.
  • BOEHRINGER INGELHEIM GMBH
  • CardioFocus
  • MORE
The global atrial fibrillation is expected to reach US$ 18,085.96 Mn in 2027 from US$ 6,446.08 Mn in 2019. The market is estimated to grow with a CAGR of 14.0% from 2020-2027.

Driving factors of the Atrial Fibrillation market are increasing prevalence of atrial fibrillation and rising awareness regarding atrial fibrillation are expected to boost the market growth over the years. Besides, development opportunities in emerging countries is expected to have a positive effect on the growth of the market in the forecast years. However, high cost of atrial fibrillation devices and procedures is likely to have negative impact on the growth of the market in the coming years.

Atrial fibrillation is among the most commonly occurring heart condition, which causes irregular and often abnormally fast heart rates, which can lead to the possibility of a stroke. A large number of populations across the globe are unaware of the symptoms associated with atrial fibrillation and hence remain untreated. As per Eastern AHSN, across England, approximately 425,000 people are living with undiagnosed and untreated AF. Various associations across the world have been involved in undertaking awareness regarding the medical condition. For instance, Health Innovation Manchester in November 2018 raised awareness regarding Atrial Fibrillation and other innovative technologies to increase the detection of the disease as part of the Global AF Aware Week.

Other than bodies such as associations and organizations, companies in the market have also played an instrumental role in increasing the awareness regarding atrial fibrillation. For instance, Biosense Webster, a Division of Johnson & Johnson, launched two major initiatives as a part of the Global AF Aware Week, which falls between 18-24 November. As a part of the action named Get Smart About AFIB (GSAAF), the company entered into a strategic partnership with the Arrhythmia Alliance to increase knowledge of AF across the healthcare community and the general public. As awareness helps in improving the medical care needed for the treatment of atrial fibrillation, the market is expected to witness considerable growth during the forecast period.

The global Atrial Fibrillation is segmented by treatment type and end user. The atrial fibrillation market, by treatment type, is segmented into non-pharmacological and pharmacological. The non-pharmacological segment held the largest share of the market in 2019. The segment is also anticipated to register the highest CAGR in the market during the forecast period.

Based on end-user, the atrial fibrillation market is segmented into hospitals, ambulatory surgical centers and cardiac catheterization laboratories. The hospitals segment held the largest share of the market in 2019. In addition, the segment is also estimated to register the highest CAGR in the market during the forecast period

Some of the essential primary and secondary sources included in the report are, Food and Drug Administration, World Health Organization (WHO), World Stroke Organization, Health Authority of Abu Dhabi, European Heart Network among others.

Reasons to Buy:
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the atrial fibrillation market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global atrial fibrillation market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott
  • AtriCure, Inc
  • Biosense Webster, Inc.
  • Biotronik Inc.
  • BOEHRINGER INGELHEIM GMBH
  • CardioFocus
  • MORE
1. Introduction
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 Global Atrial Fibrillation Market - By Treatment Type
1.3.2 Global Atrial Fibrillation Market - By End User
1.3.3 Global Atrial Fibrillation Market - By Geography

2. Atrial Fibrillation Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Atrial Fibrillation- Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America - PEST Analysis
4.2.2 Europe - PEST Analysis
4.2.3 Asia Pacific - PEST Analysis
4.2.4 Middle East and Africa (MEA) - PEST Analysis
4.2.5 South and Central America - PEST Analysis
4.3 Expert Opinion

5. Atrial Fibrillation Market - Key Dynamics
5.1 Drivers
5.1.1 Increasing Prevalence Of Atrial Fibrillation
5.1.2 Rising Awareness Regarding Atrial Fibrillation
5.2 Restraints
5.2.1 High Cost Of Atrial Fibrillation Devices and Procedures
5.3 Key Market Opportunities
5.3.1 Growth Opportunities in The Developing Nations
5.4 Future Trends
5.4.1 Development of Novel Technologies
5.5 Impact Analysis

6. Atrial Fibrillation Market - Global Analysis
6.1 Global Atrial Fibrillation Market Revenue Forecast And Analysis
6.2 Global Atrial Fibrillation Market, By Geography - Forecast And Analysis
6.3 Market Share of Key Players
6.3.1 Biosense Webster, Inc. (Johnson & Johnson)
6.3.2 Medtronic

7. Atrial Fibrillation Market Analysis and Forecast - By Treatment Type
7.1 Overview
7.2 Atrial Fibrillation Market, by Treatment Type, 2019 and 2027 (%)
7.3 Non-Pharmacological
7.3.1 Overview
7.3.2 Non-Pharmacological Market Revenue and Forecast to 2027 (US$ Mn)
7.3.3 MAZE Surgery
7.3.3.1 Overview
7.3.3.2 MAZE Surgery Market Revenue and Forecast to 2027 (US$ Mn)
7.3.4 Catheter Ablation
7.3.4.1 Overview
7.3.4.2 Catheter Ablation Market Revenue and Forecast to 2027 (US$ Mn)
7.3.5 Electric Cardioversion Market
7.3.5.1 Overview
7.3.5.2 Electric Cardioversion Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Pharmacological
7.4.1 Overview
7.4.2 Pharmacological Market Revenue and Forecast to 2027 (US$ Mn)
7.4.3 Anti-Arrhythmic Drugs Market
7.4.3.1 Overview
7.4.3.2 Anti-Arrhythmic Drugs Market Revenue and Forecast to 2027 (US$ Mn)
7.4.4 Anti-Coagulant Drugs Market
7.4.4.1 Overview
7.4.4.2 Anti-Coagulant Drugs Market Revenue and Forecast to 2027 (US$ Mn)

8. Atrial Fibrillation Market Analysis and Forecast to 2027 - End-User
8.1 Overview
8.2 Atrial Fibrillation Market, by End-User, 2019 & 2027 (%)
8.3 Hospitals
8.3.1 Overview
8.3.2 Hospitals Market Revenue and Forecast to 2027 (US$ Mn)
8.4 Ambulatory Surgical Centres
8.4.1 Overview
8.4.2 Ambulatory Surgery Centres Market Revenue and Forecast to 2027 (US$ Mn)
8.5 Cardiac Catheterization Laboratories
8.5.1 Overview
8.5.2 Cardiac Catheterization Laboratories Market Revenue and Forecast to 2027 (US$ Mn)

9. Atrial Fibrillation Market - Geographic Analysis
9.1 North America Atrial Fibrillation Market, Revenue and Forecast to 2027
9.1.1 Overview
9.1.2 North America Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.1.3 North America Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type (US$ Mn)
9.1.3.1 North America Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.1.3.2 North America Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.1.4 North America Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.1.5 North America Atrial Fibrillation Market, Revenue and Forecast to 2027, by Country (%)
9.1.6 United States
9.1.6.1 US Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.1.6.2 US Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.1.6.2.1 US Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.1.6.2.2 US Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.1.6.3 US Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.1.7 Canada
9.1.7.1 Canada Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.1.7.2 Canada Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.1.7.2.1 Canada Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.1.7.2.2 Canada Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.1.7.3 Canada Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.1.8 Mexico
9.1.8.1 Mexico Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.1.8.2 Mexico Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.1.8.2.1 Mexico Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.1.8.2.2 Mexico Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.1.8.3 Mexico Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.2 Europe Atrial Fibrillation Market, Revenue and Forecast to 2027
9.2.1 Overview
9.2.2 Europe Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.2.3 Europe Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type (US$ Mn)
9.2.3.1 Europe Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.2.3.2 Europe Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.2.4 Europe Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.2.5 Europe Atrial Fibrillation Market, Revenue and Forecast to 2027, by Country (%)
9.2.6 Germany
9.2.6.1 Germany Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.2.6.2 Germany Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.2.6.2.1 Germany Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.2.6.2.2 Germany Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.2.6.3 Germany Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.2.7 United Kingdom
9.2.7.1 UK Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.2.7.2 UK Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.2.7.2.1 UK Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.2.7.2.2 UK Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.2.7.3 UK Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.2.8 France
9.2.8.1 France Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.2.8.2 France Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.2.8.2.1 France Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.2.8.2.2 France Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.2.8.3 France Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.2.9 Spain
9.2.9.1 Spain Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.2.9.2 Spain Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.2.9.2.1 Spain Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.2.9.2.2 Spain Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.2.9.3 Spain Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.2.10 Italy
9.2.10.1 Italy Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.2.10.2 Italy Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.2.10.2.1 Italy Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.2.10.2.2 Italy Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.2.10.3 Italy Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.3 Asia Pacific Atrial Fibrillation Market, Revenue and Forecast to 2027
9.3.1 Overview
9.3.2 Asia Pacific Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.3.3 Asia Pacific Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type (US$ Mn)
9.3.3.1 Asia Pacific Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.3.3.2 Asia Pacific Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.3.4 Asia Pacific Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.3.5 Asia Pacific Atrial Fibrillation Market, Revenue and Forecast to 2027, by Country (%)
9.3.6 China
9.3.6.1 China Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.3.6.2 China Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.3.6.2.1 China Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.3.6.2.2 China Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.3.6.3 China Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.3.7 Japan
9.3.7.1 Japan Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.3.7.2 Japan Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.3.7.2.1 Japan Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.3.7.2.2 Japan Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.3.7.3 Japan Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.3.8 India
9.3.8.1 India Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.3.8.2 India Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.3.8.2.1 India Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.3.8.2.2 India Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.3.8.3 India Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.3.9 South Korea
9.3.9.1 South Korea Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.3.9.2 South Korea Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.3.9.2.1 South Korea Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.3.9.2.2 South Korea Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.3.9.3 South Korea Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.3.10 Australia
9.3.10.1 Australia Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.3.10.2 Australia Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.3.10.2.1 Australia Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.3.10.2.2 Australia Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.3.10.3 Australia Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.4 Middle East & Africa Atrial Fibrillation Market, Revenue and Forecast to 2027
9.4.1 Overview
9.4.2 Middle East & Africa Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.4.3 Middle East & Africa Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type (US$ Mn)
9.4.3.1 Middle East & Africa Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.4.3.2 Middle East & Africa Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.4.4 Middle East & Africa Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.4.5 Middle East & Africa Atrial Fibrillation Market, Revenue and Forecast to 2027, by Country (%)
9.4.6 Saudi Arabia
9.4.6.1 Saudi Arabia Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.4.6.2 Saudi Arabia Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.4.6.2.1 Saudi Arabia Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.4.6.2.2 Saudi Arabia Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.4.6.3 Saudi Arabia Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.4.7 UAE
9.4.7.1 UAE Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.4.7.2 UAE Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.4.7.2.1 UAE Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.4.7.2.2 UAE Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.4.7.3 UAE Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.4.8 South Africa
9.4.8.1 South Africa Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.4.8.2 South Africa Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.4.8.2.1 South Africa Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.4.8.2.2 South Africa Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.4.8.3 South Africa Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.5 South and Central America Atrial Fibrillation Market, Revenue and Forecast to 2027
9.5.1 Overview
9.5.2 South and Central America Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.5.3 South and Central America Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.5.3.1 South and Central America Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.5.3.2 South and Central America Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.5.4 South and Central America Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.5.5 South and Central America Atrial Fibrillation Market, Revenue and Forecast to 2027, by Country (%)
9.5.6 Brazil
9.5.6.1 Brazil Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.5.6.2 Brazil Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.5.6.2.1 Brazil Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.5.6.2.2 Brazil Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.5.6.3 Brazil Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)
9.5.7 Argentina
9.5.7.1 Argentina Atrial Fibrillation Market, Revenue and Forecast to 2027 (US$ Mn)
9.5.7.2 Argentina Atrial Fibrillation Market, Revenue and Forecast to 2027, by Treatment Type(US$ Mn)
9.5.7.2.1 Argentina Non-Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.5.7.2.2 Argentina Pharmacological Market, Revenue and Forecast to 2027, by Type (US$ Mn)
9.5.7.3 Argentina Atrial Fibrillation Market, Revenue and Forecast to 2027, by End User (US$ Mn)

10. Atrial Fibrillation Market -Industry Landscape
10.1 Overview
10.1.1 Recent Developments by Players in Atrial Fibrillation Market

11. Atrial Fibrillation Market- Key Company Profiles
11.1 Boston Scientific Corporation
11.1.1 1.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Medtronic
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 AtriCure, Inc.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Biosense Webster, Inc.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 BOEHRINGER INGELHEIM GMBH
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 CardioFocus.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Abbott
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Sanofi
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Bristol-Myers Squibb Company
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Biotronik, Inc.
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments

12. Appendix
12.1 About the Publisher
12.2 Glossary of Terms
Note: Product cover images may vary from those shown
3 of 3
  • Boston Scientific Corporation
  • Medtronic
  • AtriCure, Inc
  • Biosense Webster, Inc.
  • BOEHRINGER INGELHEIM GMBH
  • CardioFocus
  • Abbott
  • Sanofi
  • Biotronik Inc.
  • Bristol-Myers Squibb Company
Note: Product cover images may vary from those shown
Adroll
adroll